According to the positions of the Polish Society of Rheumatology 2025, patient access to innovative treatment is steadily improving. Reimbursement of biologics and synthetic targeted drugs under drug programs is mainly based on registered indications, but for some drugs and indications also includes indications not specified in the SmPC, i.e. off-label. These are in line with current medical knowledge and recommendations.
In addition to access to innovative treatment, the availability of classic drugs should also improve. Currently, the following drugs are available in Poland:
- methotrexate (p.o., s.c.),
- azathioprine,
- chloroquine,
- cyclophosphamide,
- cyclosporine,
- mycofenolate mofetil,
- leflunomide,
- sulfasalazine.
According to the Reimbursement Law, all drugs are reimbursed for the indications listed in th...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
